FDA Commissioner Makary wants to expedite biosimilar approvals. But in the U.S., the greater impediments to access have been patent disputes and payment hurdles.
FDA Commissioner Makary wants to expedite biosimilar approvals. But in the U.S., the greater impediments to access have been patent disputes and payment hurdles.